Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma

Table 1 Significantly over-expressed druggable network proteins and their associated CISs common to all non-WNT MB

Network protein	CIS	Evidence as a novel therapeutic target for MB
AURKA	CDKN2A	[1, 2]
CAD	MAP3K1
CDK4	CDKN2A	[3,4,5,6, 8]
CDK6	CDKN2A/ ZEB1	[3,4,5,6, 8]
CHEK2	PPP2R5E	[9]
P4HB	PTN
PTPRS	PTN
SLC1A5	MAP3K1	[16]
SNRPA	CDKN2A
TUBB	CDKN2A/ TJP1/ MAP3K1	[27, 28]

ISSN: 1756-994X